Veradigm Inc. · OTC:MDRX
Veradigm — Allscripts Healthcare Solutions — Merger or Acquisition (March 2022)
14 slides from Veradigm's merger presentation, Mar 3, 2022
Slide 1: Allscripts Healthcare Solutions Investor Update, March 3, 2022
Allscripts Healthcare Solutions Investor Update, March 3, 2022 Exhibit 99.1
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including the preliminary financial information included in this presentation, are based on the current beliefs and expectati
Slide 3: Announcement
Announcement Yesterday we announced that we have reached agreement to sell the net assets of our Hospitals & Large Physician Practices business segment to Harris Health, a subsidiary of Constellation Software Inc. (TSE: CSU) The Hospitals & Large Physician Practices business segment includes the Com
Slide 4: Why We Entered Into This Transaction
Why We Entered Into This Transaction Increasing Divergence in Momentum Between Our Business Segments Hospitals and Large Physician Practices Segment expected to shrink for the 3rd year in a row in 2022 Veradigm Segment growing 6-7% organically with strong competitive positioning Increasingly difficu
Slide 5: Business Segment Performance Through 12/31/21
Business Segment Performance Through 12/31/21 TTM revenue for the business segment was $928M and TTM adjusted EBITDA was $145M (see earnings press release filed 2/24/22 for reconciliation of reported adjusted EBITDA) Management expectations for the business segment in 2022: revenue for the business
Slide 6: Use of Proceeds
Use of Proceeds Net of deal related transaction costs, after-tax proceeds are expected to approximate $600 million Proceeds will be used to support continued share repurchases, as well as strategic M&A for the remaining Veradigm business
Slide 7: Veradigm Refresher
Veradigm Refresher
Slide 8: Veradigm Value Drivers
Veradigm Value Drivers VALUE Scalable Data Point-of-Care Connectivity Provider Footprint CONNECTIVITY DATA & INSIGHTS Proprietary & Partner Ambulatory Clinical data across Primary & Specialty Care ~70M patients with Linked Clinical/Claims Specialty Patient Registries FOOTPRINT Clinical Workflows Clo
Slide 9: Veradigm Footprint Provides Sustainable Advantage
Veradigm Footprint Provides Sustainable Advantage Value-Based Care Driving Market Convergence = Increased Value of Veradigm Footprint By the Numbers Full suite of Clinical, Financial, Patient Engagement and Admin solutions across Scaled National Provider Network
Slide 10: Bringing An Unmatched Provider Base to Large Market Opportunities
Bringing An Unmatched Provider Base to Large Market Opportunities Across Payer & Life Sciences Life Sciences Digital Advertising $4B $19B $4B $9B Health Plan Analytics and Services Clinical Data Exchange Specialty Medication Management $5B $11B Life Sciences Data & Analytics Descriptive, predictive
Slide 11: Diversified customer base across healthcare ecosystem
BIOPHARMA HEALTH PLANS AND PAYERS HCIT Diversified customer base across healthcare ecosystem
Slide 12: Veradigm Financial Profile
Veradigm Financial Profile Payer & Life Sciences Revenue Expected to Grow 20-25% Provider Revenue Expected to Grow 3-4% 82% 18% Total $552 Overall Revenue expected to grow 6-7% in 2022 Gross Margin of 51% and Adjusted EBITDA margin of 27% in 2021 both expected to expand in 2022
Slide 13: Revised Outlook for 2022
Revised Outlook for 2022
Slide 14: Outlook and Timing
Outlook and Timing As a result of the transaction, we are withdrawing the guidance we provided in our February 24, 2022 Outlook and replacing it with the following: We expect Veradigm revenue to grow year-over-year in a range of 6% to 7% We expect Veradigm adjusted EBITDA to grow year-over-year in a
Allscripts Healthcare Solutions — Merger or Acquisition (March 2022) on 6ix